BioSpace News Archive

REGENXBIO Inc. announced that it will host a conference call on Wednesday, May 5, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2021, and recent operational highlights.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2021 financial results and provide a corporate update on Wednesday, May 5, 2021, after the close of the U.S. financial markets.

MedAvail Holdings, Inc. a technology-enabled pharmacy company, announced it will report financial results for the first quarter 2021 on Wednesday, May 12, 2021 after market close.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced an upcoming presentation on NEON-1, the company’s Phase 1 clinical trial of ALPN-202 monotherapy at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2021 financial results will be released after the markets close on Wednesday, May 5th

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 27, 2021.

Clovis Oncology, Inc. announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021, at 5:00 p.m. Eastern time.

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that it will release first quarter 2021 financial results after the market closes on Wednesday, May 5, 2021.

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical study of XmAb564

The final results of the physician-led National Cardiogenic Shock Initiative Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization.